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ABSTRACT 
Heterozygous mutations in the human paired box 
gene PAX6 lead to impaired glucose tolerance. 
Although embryonic deletion of the Pax6 gene in 
mice leads to the loss of most pancreatic islet cell 
types, the functional consequences of Pax6 loss in 
adults are poorly defined. Here, we developed a 
mouse line in which Pax6 was selectively 
inactivated in β cells by crossing animals with 
floxed Pax6 alleles to mice expressing the 
inducible Pdx1CreERT transgene. Pax6 deficiency, 
achieved by tamoxifen injection, caused 
progressive hyperglycemia. While β-cell mass was 
preserved 8 days post injection, total insulin 
content and insulin:chromogranin A 
immunoreactivity were reduced by ~60%, and 
glucose-stimulated insulin secretion was 
eliminated. RNAseq and qRT-PCR analyses 
revealed that whereas the expression of key β cell 
genes including Ins2, Slc30a8, MafA, Slc2a2, 
G6pc2 and Glp1r was reduced after Pax6 deletion, 
that of several genes which are usually selectively 
repressed (“disallowed”) in β-cells, including 
Slc16a1, was increased. Assessed in intact islets, 
glucose-induced ATP:ADP increases were 
significantly reduced (p<0.05) in βPax6KO versus 
control  cells, and the former displayed attenuated 
increases in cytosolic Ca
2+
. Unexpectedly, glucose-
induced increases in intercellular connectivity were 
enhanced after Pax6 deletion, consistent with 
increases in the expression of the glucose sensor 
glucokinase, but decreases in that of two 
transcription factors usually expressed in fully 
differentiated β-cells, Pdx1 and Nkx6.1, as 
observed in islet “hub” cells. These results indicate 
that Pax6 is required for the functional identity of 
adult  cells. Furthermore, deficiencies  cell 
glucose-sensing are likely to contribute to defective 
insulin secretion in human carriers of PAX6 
mutations.  
INTRODUCTION 
Defective insulin secretion underlies all forms of 
diabetes mellitus, a disease which now affects more 
than 422 m individuals worldwide (WHO: 
http://www.who.int/mediacentre/news/releases/201
6/world-health-day/en/). Insulin is stored and 
released from  cells within pancreatic islets of 
Langerhans following elevations in glucose 
concentration (1). In response to high glucose, 
enhanced flux through glycolysis and 
mitochondrial oxidative metabolism (2) leads to 
increases in cytosolic ATP/ADP concentrations, the 
closure of ATP-sensitive K
+
 (KATP) channels (3), 
cellular depolarisation and Ca
2+
 influx (4). Ca
2+
 
sensors on secretory granules then catalyse 
hormone release through exocytosis (5). In the 
context of the intact islet,  cell- cell connections 
(6,7) then create a coordinated network ensuring 
the optimal regulation of secretion through 
propagation of Ca
2+
 and other signals (8).  
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Paired box 6 (PAX6) is a transcription factor 
crucial for the development of the eye, brain, 
olfactory system and endocrine pancreas. 
Heterozygous mutations in the PAX6 gene, which 
result in the production of a truncated, non-
functional protein (9), cause abnormal iris 
formation (Aniridia) and impaired glucose 
tolerance (10). Correspondingly, PAX6 binding 
domains are found in the promoter regions of 
several key  cell genes (11), and islets derived 
from a human pedigree harbouring an inactivating 
missense PAX6 mutation are deficient in proinsulin 
processing enzymes (PCSK1/3) (12). Interestingly, 
we observed no changes in Pcsk1 expression in the 
present studies, arguing that the alterations 
observed in man may reflect an indirect action of 
PAX6. Furthermore, inheritance of the G allele at 
the single nucleotide polymorphism rs685428 
lowers PAX6 expression in man and is associated 
with increased fasting insulin and lower 
proinsulin:insulin ratio (13). 
In mice, homozygocity for the ‘small eye’ Pax6 
mutant allele (Sey
Neu
) leads to death at perinatal 
stages, and affected animals have dramatically 
reduced numbers of all islet cell types (14). Whilst 
deletion throughout the pancreas leads to overt 
diabetes and loss of  cells (15), heterozygous loss-
of-function mutants show age- (12) and diet- (16) 
dependent impairments in glucose tolerance. 
Finally, Pax6 expression is decreased in a rat 
model of T2D (the Zucker diabetic fatty rat; ZDF) 
(17)  
Recent studies have also indicted that PAX6 may 
be important in maintaining the differentiated state 
and identity of the adult  cell. Thus, conditional 
inactivation of Pax6 at post-natal stages in mice 
with a tamoxifen-inducible ubiquitous Cre leads to 
the development of a severe diabetic phenotype 
(18). Pancreatic analysis revealed a reduction in the 
expression of the insulin 1 and insulin 2, glucagon 
and somatostatin genes coupled with increases in 
the number of ghrelin-positive cells (18). The latter 
were also increased when deletion was restricted to 
either α or  cells in adult mice (19). 
By contrast, few studies have examined how Pax6 
deletion affects the functional maturity of the adult 
 cell. One report (20), based on RNA interference, 
provided evidence that Pax6 is required in the adult 
rat  cell for normal insulin secretion and the 
expression of key genes including Ins1 and Ins2. 
However, the above approach was complicated by 
the requirement for  cell isolation prior to gene 
silencing, , and by potential off-target effects of 
silencing RNAs. Further, glucose sensing was 
examined in the latter study using isolated  cells 
rather than the intact islet, where responses to 
stimulation can differ markedly, and the gain of 
function resulting from inter-cellular interactions 
across the islet syncytium is lost (21). On the other 
hand, studies on the impact of Pax6 deletion using 
Cre-mediated recombination in the adult have used 
either a ubiquitous Cre (18) or Cre expression 
driven by the rat insulin 2 promoter (RIP), which 
also leads to substantial recombination in the brain 
(22).  
The aims of the present work were therefore: (i) to 
achieve efficient Pax6 deletion selectively in the 
adult mouse  cell using targeted recombination at 
floxed alleles with an alternative tamoxifen-
inducible Cre system (Pdx1CreERT) (23,24); (ii) to 
examine  cell function and glucose-sensing in vivo 
and in vitro after Pax6 ablation, and (iii) to 
determine the role of PAX6 in the control of a 
broader range of genes than has previously been 
examined, including those which are normally 
selectively silenced, or “disallowed”, in mature β 
cells (25,26). Alongside decreases in the expression 
of β cell signature genes, up-regulation of the latter, 
which occurs in type 2 diabetes (27,28), is likely to 
report a loss of normal cellular identity. 
We show that Pax6 deletion achieved in this way 
leads to profound diabetes, consistent with earlier 
findings using alternative Cre drivers. Critically, 
we demonstrate marked abnormalities in gene 
expression, glucose metabolism, Ca
2+
 dynamics 
and insulin secretion in βPax6KO mouse islets 
early in the development of diabetes, which are 
likely to play an important part in  cell secretory 
failure. Unexpectedly, islets null for Pax6 in the  
cell display normal or enhanced cellular 
interconnectivity. Thus a functionally-
interconnected  cell network can be maintained 
despite the partial loss of full  cell identity. 
 
RESULTS 
Efficient and inducible deletion of Pax6 from the 
adult mouse  cell 
Mice harbouring LoxP sites surrounding exons 5, 
5a and 6 of Pax6 were crossed to Pdx1CreER mice. 
The breeding strategy used resulted in all animals 
carrying two copies of the floxed Pax6 gene, but 
only half of these animals possessed a Cre allele 
(Cre
+
; Pax6
fl/fl
::Pdx1CreERT
+/-
; βPax6KO). 
Tamoxifen is expected to result in gene deletion 
only in animals that possess the Cre transgene 
(Figure 1A).  
Eight week-old Pax6
fl/fl
::Pdx1CreERT
+/- 
and
 
control 
Pax6
fl/fl
::Pdx1CreERT
-/- 
littermates were injected 
daily with tamoxifen (2 mg) for five days. Islets 
isolated two weeks after the final tamoxifen 
injection showed substantially (~70%) reduced 
levels of Pax6 mRNA compared to littermate 
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controls (Figure 1B; 1.00 ± 0.00 vs. 0.35 ± 0.16 for 
Cre
- 
vs. Cre
+
; fold-change vs. Cre
-
; p<0.01), 
consistent with deletion from the majority of the 
islet β cell compartment (~ 60 % of all cells) (29). 
A comparable reduction in PAX6 
immunoreactivity was also observed by Western 
(immuno-) blotting (Figure 1C).  
Immunocytochemical analysis of pancreatic slices 
for PAX6, insulin and glucagon assessed 8 days 
after the first tamoxifen injection (Figure 1D), 
revealed an ~80 % decrease in PAX6 staining 
across all islet cells (Fig. 1 D,E) with essentially 
complete (>98%) elimination of PAX6 
immunoreactivity from β-cells and a more minor 
reduction (~25%) in α-cells (Fig. 1D,F), 
presumably reflecting maintained expression of 
Pdx1 in a minority of α-cells, some of which may 
also express other islet hormones (30). We note 
that this Cre deleter strain does not catalyse 
significant recombination in the hypothalamus (31). 
Despite a dramatic decrease in insulin 
immunoreactivity on a per cell basis (Figure 1D, g 
vs c) immunocytochemical analysis (Figure 1G), 
assessed at the same time point, revealed no 
significant changes in total β cell mass (Figure 1G; 
0.23 ± 0.05 % vs control 0.17 ± 0.02 %; ns; 
Student’s t test; n=4 animals per genotype), α cell 
mass (Figure 1H; 0.069 ± 0.019 % vs control 0.031 
± 0.004 %; ns; Student’s t test; n=4) or β to α cell 
ratio (Fig. 1I; 4.3 ± 1.5 vs control 5.5 ± 0.9; ns; 
Student’s t test; n=4). 
Deletion of Pax6 impairs glucose homeostasis in 
vivo 
βPax6 KO mice showed increased blood glucose 
levels from 8 days post final tamoxifen injection 
(Figure 2A; 9.45 ± 0.35 mM vs. 26.15 ± 1.13 mM 
for Cre
-
 vs. Cre
+
 respectively). This change was 
further exacerbated over time, with βPax6KO 
animals showing an average glycaemia of 50.0 mM 
at the time of termination. Consistent with overt 
diabetes, the body weight of βPax6KO mice began 
to decline seven days after the final tamoxifen 
injection (Figure 2B). Two weeks post tamoxifen 
treatment, the decline in body weight was so severe 
that βPax6KO mice were terminated in accordance 
with UK Home Office guidelines. We note that 
expression of the Pdx1CreERT transgene alone is 
not expected to impact insulin secretion or glucose 
tolerance (32). Correspondingly, 
Pax6
fl/fl
::Pdx1CreERT
+/- 
mice remained 
normoglycemic in the absence of tamoxifen 
administration (not shown). Likewise, tamoxifen 
alone, at the doses used here, exerts no effect on 
glycemia in wild-type C57BL/6J mice (31). Hence, 
any metabolic changes observed can reasonably be 
ascribed to the deletion of Pax6. 
Insulin sensitivity, as assessed by intraperitoneal 
insulin tolerance test, was not markedly affected by 
Pax6 deletion in β cells, despite increased blood 
glucose levels (Figure 2C). However, upon 
termination two weeks post tamoxifen treatment, 
blood glucose levels were significantly higher in 
βPax6KO animals than littermate controls (Figure 
2D; 9.10  0.14 mM vs.47.2  0.04 mM for Cre- vs. 
Cre
+
; p<0.001). This change was accompanied by 
significantly decreased plasma insulin levels 
(Figure 2E; 1.51 ± 0.15 ng/mL vs 0.83 ± 0.16 
ng/mL for Cre
-
 vs. Cre
+
; p<0.05) suggesting that 
the observed hyperglycaemia, caused by Pax6 
deletion, is likely to be due to insufficient insulin 
output from pancreatic  cells.  
Total insulin levels, as measured in islets isolated 
from animals one week post tamoxifen treatment, 
were significantly reduced by Pax6 deletion 
(Figure 2F; 14.5 ± 2.97 ng/mL/islet vs. 6.28 ± 1.57 
ng/mL/islet for Cre
-
 vs. Cre
+
 respectively; p<0.05). 
A similar reduction, to levels observed after 
incubating at 3 mM glucose, was apparent after 
normalisation to islet DNA content (660 ± 63 vs  
322 ± 69 ng insulin/ng DNA, p<0.05) or to total 
insulin content (0.41 ± 0.03 vs 0.016 ± 0.03 %, p 
<0.01). The latter observation excludes the 
possibility that our failure to detect an increase in 
insulin secretion from βPax6KO islets after 
incubation at 17 vs 3 mM glucose simply reflects 
the lowered insulin content of KO vs control islets.  
Finally, we measured basal and glucose-stimulated 
insulin secretion from isolated islets (Fig. 2G). 
Release of insulin from βPax6KO islets tended to 
be lower than that from control islets when 
measured at 3 mM glucose but, in contrast to the 
~4-fold stimulation observed in wild type islets at 
17 mM glucose, no further increase was detectable 
from βPax6KO islets at this higher glucose 
concentration (Fig. 2G). This altered response was 
not associated with any marked redistribution of 
granules away from the plasma membrane (i.e. in a 
reduction in the number of “morphologically-
docked” granules), as assessed by TIRF 
microscopy (Fig. 2H,I), suggesting that defects 
later in granule release, or in the generation of 
metabolic signals required for exocytosis, are 
defective in this model.  
Deletion of Pax6 alters the expression of  cell 
signature and disallowed genes 
Consistent with a loss of  cell identity, the 
expression of Ins2, Slc30a8, MafA, Slc2a2 and 
Glp1r, signature genes which are all highly 
expressed in healthy β cells and are essential for 
normal function (1), were all significantly reduced 
by Pax6 deletion 8 days after tamoxifen treatment, 
as assessed by qRT-PCR analysis (Figure 3 A-E; 
p<0.05 vs. Cre- for all genes). In contrast, the 
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expression of the glucose sensor glucokinase (Gck ) 
tended to increase (Figure 3F, ns vs. Cre
-
). 
Interestingly, the expression of the β cell 
“disallowed” gene Slc16a1, encoding 
monocarboxylate transporter 1 (MCT-1), was 
significantly increased by Pax6 deletion (Figure 
3G, p<0.05 vs. Cre
-
) at this stage. However, the 
expression of Ldha, another disallowed gene, was 
not affected (Figure 3H, p>0.05 vs. Cre
-
). 
As expected based on earlier models (18,19), 
glucagon expression was not significantly altered 
by Pax6 deletion from  cells (Figure 3J, ns vs. 
Cre
-
). Correspondingly, fasting plasma glucagon 
levels were also unchanged between control and 
Pax6 null animals (147 ± 49.6 and 128 ± 28.7 
pg/mL in control and βPax6KO mice; n=4 and 6 
animals respectively; p>0.05). In contrast, ghrelin 
expression was dramatically (>40 fold) increased 
(Figure 3K, p<0.05 vs. Cre
-
).  
To provide a transcriptome-wide assessment of the 
impact of Pax6 deletion we next performed 
massive parallel RNA sequencing (RNAseq) on 
islets from control or null animals (Supplemental 
Figure S1). This revealed, firstly, that disallowed 
genes were selectively enriched amongst the up-
regulated genes from βPax6KO islets, as assessed 
by GSEA (Supplemental Figure S1A). Thus, of 58 
members of the disallowed gene family included in 
the analysis (25), 38 were significantly enriched. 
These included both founder members of the group 
(Slc16a1 and Ldha) (33) as well as the four other 
members (Pdgfra, Cxcl12, Igfbp4 and Oat) of the 
shorter list of six genes common to (25,26) 
(Supplemental Figure S1B).  
RNAseq also demonstrated that whereas markers of 
β cell progenitors, notably Neurogenin3, were up-
regulated in response to the loss of PAX6, 
transcription factors characteristic of the fully 
differentiated β cell, including Nkx6.1, Pdx1 and 
MafA, were repressed in knockout islets 
(Supplemental Figure S1C). Interestingly, these 
observations suggest that PAX6 may serve as either 
an activator or a repressor depending on context 
and target, as recently shown for the β cell enriched 
factors RFX6 (34) and Nkx2.2 (35). 
The above approach also corroborated the changes 
observed above, including in the expression of 
ghrelin (increased 32-fold), Ins2 (decreased 5.5-
fold) and Gck (increased 2.8-fold) after Pax6 
deletion. Gcg, Ppy, SSt, expression were barely 
altered (Supplemental Figure S1D) and Pcsk1 and 
Pcsk2 mRNA levels were essentially unchanged 
(Supplemental Figure S1E), arguing against 
alterations in prohormone processing. Affected 
genes included Ero1lb, a protein disulphide 
isomerise strongly enriched in β cells and likely 
involved in insulin maturation (36), and G6pc2, 
involved in glucose sensing (37), each being 
significantly down-regulated (Supplemental Figure 
S1E). Of note, we observed a large (156-fold; 
P=1.5x10
-215
) increase in the expression of the 
voltage-gated potassium channel Kcnj5, likely to 
exert significant effects on membrane excitability 
and thus Ca
2+
 dynamics (Supplemental Figure 
S1E).  
βPax6KO islet cells lose insulin expression but 
retain neuroendocrine properties 
Previous reports (19), and the above findings, 
indicate that Pax6 null  cells are shunted towards 
an alternative cell fate. We therefore stained 
pancreatic slices obtained from animals eight days 
after the final tamoxifen injection for the 
neuroendocrine marker chromogranin A (38) 
alongside insulin and glucagon (Figure 4A). 
Expressing the number of total insulin and 
glucagon immunopositive area as a ratio of the total 
chromogranin A immunopositive area revealed that 
deletion of Pax6 significantly reduced the 
insulin:chromogranin A ratio (Figure 4B; 0.89 ± 
0.02 vs. 0.38 ± 0.02 for Cre
-
 vs. Cre
+
 respectively; 
p<0.001), while the glucagon:chromogranin A ratio 
was not significantly changed (Figure 4C; 0.14 ± 
0.04 vs. 0.19 ± 0.02 for Cre
-
 vs. Cre
+
; ns). 
Islets isolated from βPax6KO mice show impaired 
glucose-induced cytosolic ATP/ADP increases and 
intracellular Ca
2+
 dynamics 
Given the absence of glucose-stimulated insulin 
secretion, and changes in gene expression and 
apparent cellular identity observed above, we next 
determined whether disruption of Pax6 may 
interfere with glucose metabolism or sensing by  
cells within the intact islet. We used firstly the 
recombinant cytosol-targeted ATP/ADP probe, 
Perceval (39,40), and Nipkow spinning disc 
confocal microscopy (41,42). Expression of the 
above sensor is largely restricted to the  cell [34], 
due to the apparent tropism of adenoviruses 
towards this cell type (43). Exposure to high (11 
mM) glucose caused a time-dependent increase in 
ATP/ADP ratio in control islets as expected 
(40,41), and this increase was reduced in amplitude 
by ~30% in βPax6KO islets (Figure 5A, B; 0.15 ± 
0.01 arbitrary units (AU)
1
 vs. 0.11 ± 0.01 AU for 
Cre
-
 vs. Cre
+
 respectively; p<0.05, and 
Supplemental Movies 1 & 2). Pax6 deletion also 
markedly reduced the number of glucose-
responsive cells, as assessed at 11 mM glucose 
(Figure 5C & D; 53.9 ± 4.93 vs. 25.8 ± 2.30 for 
Cre
-
 and Cre
+
, respectively, p<0.001). Similar 
                                                          
1
 Abbreviations: AU, arbitrary units; GSEA, Gene 
Set Enrichment Analysis; KATP, ATP-sensitive K
+
 
channel 
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differences between βPax6 null and control islets 
were also apparent after stimulation at a lower 
glucose concentration (8 mM; Figure 5E,F; 0.07 ± 
0.01 vs 0.02 ± 0.005 AU30 for Cre
-
 and Cre
+
, 
respectively, p<0.001).. 
Since impairments in ATP generation are likely to 
affect the closure of KATP channels, impacting on 
plasma membrane depolarisation and Ca
2+
 influx 
(1), we next sought to determine how intracellular 
Ca
2+
 dynamics may be affected by Pax6 deletion. 
Islets were therefore loaded with the trappable 
intracellular Ca
2+
 probe, fluo-2, and confocal 
imaging performed essentially as above (albeit at a 
higher acquisition rate). Pax6 deletion reduced both 
the amplitude (Figure 6A; 0.90 ± 0.13 AU vs. 0.33 
± 0.04 AU for Cre
-
 vs. Cre
+
 respectively; p<0.001) 
and the area-under-the-curve (AUC; Figure 6A; 
2819.8.1 ± 118.1 AU vs. 2248 ± 54.9 AU for Cre
-
 
vs. Cre
+
; p<0.001) of glucose-evoked Ca
2+
 traces. 
Ca
2+
 responses to the depolarising stimulus KCl 
were unchanged by Pax6 deletion (Figure 6B; 
Amplitude: 1.35 ± 0.13 AU vs.1.43 ± 0.12 AU for 
Cre
-
 vs. Cre
+
 respectively; AUC 1552 ± 60.2 vs. 
1569 ± 61.1 for Cre
-
 vs. Cre
+
 respectively; both 
ns), suggesting that voltage-dependent Ca
2+
 
channel function remains intact.  
Individual  cell Ca2+ responses in βPax6KO islets 
show high levels of coordination 
Although average islet Ca
2+
 responses to glucose 
were reduced by Pax6 deletion (Figure 6A), the 
responses of individual β cells were also altered. 
Specifically, islet  cells derived from Cre- animals 
responded to glucose with a rapid and largely 
monophasic increase in free cytosolic Ca
2+
 that was 
synchronised across the islet (Figure 7A, top, and 
Supplemental Movie 3). By contrast, βPax6KO  
cells displayed a delayed and oscillatory response, 
although one which was well coordinated between 
individual  cells (Figure 7A, bottom, and 
Supplemental Movie 4). Subjecting individual  
cell responses to analysis packages that map cell-
cell coordination (8,44,45), it was possible to show 
that the percentage of cells that responded to 
glucose was unchanged by Pax6 deletion (Figure 
7B; 77.6 ± 5.39 % vs. 72.1 ± 4.81 % for Cre
-
 vs. 
Cre
+
 respectively; ns). However, the level of 
synchronicity between individual  cells tended to 
be higher in βPax6KO islets, as shown by an 
increase in the percentage of significantly 
correlated cell pairs (Figure 7C; 69.1 ± 7.40 % vs. 
84.7 ± 3.79 % for Cre
-
 vs. Cre
+
 respectively; 
p=0.06). Furthermore, the strength of  cell 
connections was greater in βPax6KO islets, as 
shown by weighted graphs depicting location and 
strength of connections between individual cells 
(Figure 7D,E; 0.42 ± 0.09 R vs. 0.65 ± 0.04 R for 
Cre
-
 vs. Cre
+
 respectively; p<0.05). These changes 
were not associated with any alterations in the level 
of expression of the gap junction protein connexin 
36, encoded by Gjd2, an important mediator of 
cell-cell interactions in the islet (7) (Figure 3I).  
 
DISCUSSION 
The present study sought to determine whether 
changes in cellular identity, previously described 
after Pax6 inactivation in  cells (18,19), are 
accompanied by significant changes in  cell 
function, as well as the expression of key β cell 
genes involved in normal glucose sensing and 
insulin release. We also sought to determine the 
importance of Pax6 in maintaining intercellular 
communication within the islet, a feature required 
for normal secretory responses to secretatogues and 
which becomes defective in type 2 diabetes (21).  
The use here of the efficient and selective 
Pdx1CreERT driver line (23,24,31) led to the more 
rapid (within days of tamoxifen treatment) and 
severe (>50 mM) hyperglycaemia than previously 
observed after Pax6 deletion either globally (18) or 
in  cells using the more promiscuous rat insulin 
promoter 2 (RIP2) Cre driver (19). Although 
limited recombination in the brain (chiefly in the 
basomedial hypothalamus) is also observed with 
Pdx1CreERT (22), deletion at extrapancreatic sites 
(19,22,46), or in islet non- cells, may contribute to 
the milder phenotypes previously observed with 
earlier Cres. Whilst recombination with 
Pdx1CreERT has previously been reported to be 
almost completely confined to  cells (24), we did 
detect a small degree of deletion of PAX6 in α 
cells. This difference with respect to earlier 
findings may reflect the differing susceptibility to 
Cre action of LoxP sites at different genomic 
locations (47). Of note, glucagon mRNA levels 
were not different between WT and KO mice (Fig. 
3J Supplemental Figure S1D)). On the other hand, 
we observed a substantial increase in ghrelin 
expression (Fig. 3 K, Supplemental Figure S3D) 
after Pax6 deletion which may reflect a cell fate 
switch of  (or possibly α) cells towards an ε cell 
phenotype, as previously proposed (19).  
We consequently chose to study islets from 
βPax6KO mice at relatively early time points after 
deletion to minimise the exposure in vivo to high 
glucose concentrations. This was felt important 
given earlier (48) and more recent (49) reports that 
hyperglycemia itself leads to a loss of  cell 
identity. Although at the time point post tamoxifen 
used in the present studies (8 days) a significant 
increase in fasting blood glucose was apparent 
(Figure 2), the alterations in insulin and glucagon 
expression observed after Pax6 deletion were 
markedly different in both extent (insulin) and 
direction (glucagon) from those previously reported 
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in response to hyperglycemia induced by KATP 
channel activation in  cells (49). Moreover, in the 
present report, islets were cultured at near normal 
(11 mM) glucose for 24-48 hours after extraction, a 
manoeuvre expected to at least partially reverse any 
changes resulting from antecedent in vivo 
hyperglycemia. Finally, we observed no (qRT-
PCR; Fig. 3H) or small (RNAseq; Supplemental 
Figure S1B) increases in Ldha expression, 
previously found to be reversibly up-regulated in 
vivo in islets by hyperglycemia (48). Thus, we 
conclude that alterations in gene expression and 
function observed in the present study are, at least 
in large part, a reflection of cell autonomous 
actions of Pax6 rather than hyperglycemia per se. 
Notably, the expression of several key  cell genes 
was affected by Pax6 ablation, with substantial 
decreases in Ins2, Slc30a8 (ZnT8), MafA, Slc2a2 
(Glut2) and Glp1r mRNA levels (Figure 3). Whilst 
future work will be required to determine whether 
this reflects direct or indirect regulation of these 
genes by PAX6, we note that Gck gene expression 
was increased (Fig. 3F), demonstrating a degree of 
selectivity in the regulation of  cell-enriched genes 
by PAX6.  
Interestingly, we also demonstrate that, after Pax6 
inactivation, a significant increase occurs in the 
expression of members of the β cell “disallowed” 
gene family, notably Slc16a1/MCT-1 (27). As far 
as we are aware, this is the first time that Pax6 has 
been shown to regulate members of this group. 
Thus, PAX6 controls  cell identity both through 
driving the expression of essential glucose-sensing 
genes and by repressing a gene whose presence is 
deleterious to β cell function (50). In this respect, 
the actions of PAX6 resemble those of RFX6, 
shown recently to be necessary for both normal  
cell development (51) and function (34).  
Although, and in agreement with previous studies, 
total islet insulin content was reduced by Pax6 
deletion by ~60 % (Figure 2F), we were unable to 
detect any insulin secretion from Pax6 null islets in 
response to glucose. Interestingly, and although 
explored in a relatively small number of animals 
(n=4/genotype), this was not associated with 
detectable decreases in overall β or α cell mass or 
in β/α cell ratio (Figure 1, G-I). Deploying cell-
resolution  imaging approaches, we demonstrate 
that this is associated with marked impairments in 
glucose-induced ATP/ADP increases, likely 
resulting from lowered Glut2 (Slc2a2), but not Gck 
expression (which was increased), and possibly 
increases in Slc16a1/MCT-1 levels, thus favouring 
anaerobic glycolysis.  We also noted a substantial 
decrease in the expression of G6pc2 (Figure 3N), 
likely to potentiate the effects of increased Gck 
expression and thus to increase net flux from 
glucose to glucose-6P.  Since flux control at the 
initial stages of glycolysis is achieved chiefly at the 
glucokinase step (1), the above observations 
suggest that increased flow through the latter 
reaction is not met by a proportional increase at 
later stages of glycolysis or in the oxidation of 
pyruvate and NADH by mitochondria. Future 
studies will be needed to explore these possibilities 
in detail. 
Of note, increased expression and release of 
ghrelin, and binding to ghrelin receptors which are 
enriched in delta cells (52) may also enhance 
somatostatin secretion to suppress insulin release. 
Deletion of Pax6 also drastically changed the 
profile of glucose-stimulated Ca
2+
 responses from 
an initial spike of Ca
2+ 
activity followed by a 
sustained, oscillatory period (34,53) to more 
delayed and burst-like properties reminiscent of 
those observed in α cells (54). Interestingly, 
connectivity between cells was not significantly 
impaired by the loss of Pax6. Rather, we observed 
a tendency towards increased connectivity, and a 
significant increase in the strength of connections 
between cells (correlation coefficient; Figure 
7D&E), despite unchanged Gjd2 expression 
(Figure 3I). Thus, impaired  cell- cell 
communication/connectivity does not drive altered 
glucose sensing in Pax6 null  cells. Importantly, 
the present findings demonstrate that full  cell 
maturity is not a prerequisite for the formation of a 
functional interconnected network of cells. Indeed, 
we have recently shown the existence of a small 
population of immature  cells that express high 
levels of glucokinase and which dictate islet 
responses to glucose (55). Whether and how the 
activity of these putative “hub” or “pacemaker” 
cells within the islet is affected by Pax6 deletion 
will be interesting to establish. Of note, elevated 
Gck expression, alongside substantially lower Pdx1 
and Nkx6.1 expression, in βPax6KO islets, are 
features characteristic of previously-described islet 
“hub” cells (55). These and other changes, 
including in ion channel expression (RNAseq; see 
Results and not shown), and glucose sensitivity, 
may thus contribute to the enhanced Ca
2+
 dynamics 
and connectivity observed after Pax6 deletion.  
Perhaps surprisingly, the partial defects in 
metabolic glucose signalling observed above (i.e. 
ATP/ADP and Ca
2+
 changes) were associated with 
an apparently complete loss of glucose-stimulated 
insulin secretion, assessed in vitro. This loss of 
insulin release was less marked in vivo, possibly 
reflecting alternative mechanisms for stimulating 
secretion in the living animal (e.g. actions of 
circulating amino acids or fatty acids, hormonal 
and neural inputs into the islet, etc) (1). 
Nevertheless, the results obtained with isolated 
islets would appear to indicate that PAX6 is also 
important in the β cell for KATP channel and Ca
2+
-
independent mechanisms of glucose-stimulated 
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insulin secretion (56). Whether enhanced β cell-β 
cell coupling can, in some settings, also be 
deleterious for the normal tight regulation of 
insulin secretion, is a possibility which also merits 
investigation.  
Whilst the current study was under revision, a 
report (57) appeared using a similar approach but 
an alternative Cre (MIP.CreERT), based on the rat 
insulin 1 promoter, to delete Pax6 in adult β cells. 
Importantly, Swisa et al (57) also identified, by 
Gene Ontology analysis, gene classes which may 
contribute to the enhanced connectivity observed in 
the present report, including ion channels and Ca
2+
 
channels. As observed here, the phenotype of β 
Pax6 null mice was remarkably severe, and was 
associated with ketosis and marked changes in 
secretory granule structure observed at the 
ultrastuctural level by electron microscopy. Thus, 
atypical granules, lacking a classical “halo” around 
the dense core, were frequently seen in null mouse 
islets. Importantly, lineage tracing work in the 
report by Swisa et al also demonstrated that 
“reprogammed” cells, expressing ghrelin, were 
derived from β cells. Finally, it was shown by 
ChIP-sequencing that PAX6 binds directly to 
sequences in target genes to affect their repression 
or activation. Importantly, however, the above 
study did not explore the regulation of insulin 
secretion or metabolic glucose signalling in Pax6-
deleted β cells, as described in the present report. 
As discussed above and elsewhere (58), use of the 
MIP.CreERT deleter strain may, however, be 
complicated by the concomitant over-expression of 
human growth hormone (hGH). Reassuringly, the 
strong similarities between the findings of our own 
study and those described in (57) indicate that the 
changes in each are chiefly attributable to altered 
Pax6 expression. 
 
EXPERIMENTAL PROCEDURES 
Generation of βPax6KO mice 
All animal procedures were approved by the Home 
Office according to the Animals (Scientific 
Procedures) Act 1986 of the United Kingdom (PPL 
70/7349).  
Mice homozygous for the floxed allele of Pax6 
(Pax6
fl/fl
),
 
kindly provided by Prof David Price, 
University of Edinburgh (59), were crossed to a 
tamoxifen-regulated deleter strain, provided by Dr 
Doug Melton (Harvard Medical School) in which 
Cre recombinase is expressed under the control of 
the Pdx1 promoter (Pdx1CreERT) (23). The 
breeding strategy ensured that 50% of the offspring 
inherited the Cre transgene (Cre
+
, βPax6KO; 
Pdx1CreERT
+/-
::Pax6
fl/fl
), the remainder serving as 
littermate controls (Cre
-
, Pdx1CreERT
-/-
::Pax6
fl/fl
). 
Gene deletion was achieved by five intraperitoneal 
tamoxifen injections (2 mg), administered daily to 
eight week old animals of both genotypes. 
Pdx1CreERT
+/- 
mice displayed no evident 
metabolic abnormalities.  
Insulin tolerance tests (ITT) 
Bovine insulin (0.75 U/Kg body weight; Sigma, 
Dorset, UK) was injected into the abdomen of mice 
fasted for 5 hours. Blood glucose measurements 
were taken at time points 0, 15, 30 and 60 min. 
using an automatic glucometer (Accucheck).  
Plasma Glucose & Insulin Measurements 
Fed mice were culled and blood collected into 
EDTA coated tubes (Sarstedt, Beaumont Leys, 
UK). Glucose measurements were determined 
using an automatic glucometer (Accucheck). For 
insulin measurements, plasma was separated by 
centrifugation at 13,200 rpm. for 20 min, 5 μL of 
blood plasma was used to measure insulin levels 
using an ultrasensitive mouse insulin ELISA kit 
(CrystalChem, Netherlands). For total islet insulin 
measurements, five islets were lysed by sonication 
in acidified ethanol (1.5% HCl [vol./vol.], 75% 
ethanol [vol./vol.], 0. 1 % Triton X-100 [vol.vol]). 
Insulin concentration was determined using a 
HTRF-based assay kit (CisBio, USA). 
Quantitative real time PCR (qRT-PCR) 
RNA was extracted from isolated islets using 
Trizol reagent (Invitrogen, Paisley) and reverse 
transcribed using a high capacity reverse 
transcription kit (Invitrogen, Paisley). Relative 
gene expression was assessed using SYBR Green 
(Invitrogen, Paisley) and expression of each gene 
was normalized and expressed as n-fold change in 
mRNA expression versus Cre
-
, calculated using the 
2^
ΔΔCt 
method (60). 
Massive parallel sequencing of RNA (RNAseq) 
Total RNA was extracted with Trizol from islets 
isolated from five knockout and four control mice. 
Polyadenylated transcripts were selected during the 
preparation of paired - end, directional RNA-Seq 
libraries. Libraries were sequenced on an Illumina 
HiSeq 2000 machine. The quality of the sequenced 
libraries was assessed using fastQC. Reads were 
mapped to the Grc38m assembly using HiSat2. 
Annotated transcripts were quantified using 
featureCounts and differentially expressed genes 
identified with DESeq2. All genes were ranked by 
fold-change and the resultant list used for gene set 
enrichment analysis. Gene Set Enrichment Analysis 
(GSEA) was performed essentially as described 
(61) and used the Broad Institute GSEA tool for 
analysis of pre-ranked lists 
http://software.broadinstitute.org/gsea/msigdb) 
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with a custom constructed geneset combining the 
disallowed genes identified in (25,26) 
RNA-Seq accession codes 
Raw sequence data for RNA-Seq will be made 
available via deposition to ArrayExpress 
(www.ebi.ac.uk/arrayexpress; Accession number 
xxxx). 
Immunocytochemistry 
Pancreata were extracted and fixed in 10% 
[vol./vol.] formalin, transferred into a tissue 
processing cassette and embedded in paraffin wax 
within 24 hours of being harvested from the mouse. 
Pancreatic sections were cut at 5 μm onto 
superfrost slides. Sections were dewaxed by 
immersing in histoclear (Sigma Aldrich, Dorset, 
UK) for 20 min before rehydration. Antigen 
retrieval was performed by boiling slides in citrate 
buffer (VectorLabs, Peterborough, UK), washed 
before blocking 3% [vol./vol.] goat/donkey serum 
(Dako, Cambridgshire, UK) in 2% BSA with 0.1% 
[vol./vol.] Triton-X100 for 1 h at room 
temperature. Slides were then washed before 
staining with primary antibody (guinea pig anti-
insulin (1:200, DAKO), mouse anti-glucagon 
(1:1000, Sigma Aldrich), and rabbit anti-
chromagranin A (1:200, Abcam). Slides were 
incubated in primary antibody overnight at 4 ⁰C. 
Revelation was performed using a combination of 
the following secondary antibodies: donkey anti-
rabbit 488, goat anti-guinea pig 643, goat anti-
mouse 568 (all 1:500, Invitrogen, Paisley, UK). 
Slides were mounted using vectorshield mounting 
medium containing DAPI (Vectorlabs, 
Peterborough, UK) and a 24 mm coverslip placed 
over the slice. Slides were visualised by fluorescent 
microscopy using a Zeiss Axio Observer inverted 
widefield microscope with LED illumination 
running Zen acquisition software. Quantification of 
immunopositive area was achieved using ImageJ 
analysis software using a macro established in 
house.  For quantification of β- and α-cell mass, 
slides were visualized using an Axiovert 200M 
microscope (Zeiss) with Alexa Fluor 488 goat anti-
guinea pig IgG and with Alexa Fluor 568 goat anti-
mouse IgG (Invitrogen) using an Axiovert 200 M 
microscope (Zeiss, Welwyn Garden City, UK) at 
the Facility for Imaging by Light Microscopy 
(FILM), Imperial College London. 
In order to stain PAX6 an alternative protocol was 
used, based on a modification of the protocol 
described in (62). The main adaptions included 
permeabilisation with methanol [100%; -20°C] (3 
min), more vigorous antigen retrieval via boiling in 
citrate-based antigen unmasking solution (Vector 
Laboratories; 15 min), enhanced blocking with 1% 
(w/v) skimmed milk (1.5 h), incubation with anti-
glucagon antibody (1:500) alone 2.5 h before 
overnight incubation with remaining two primary 
antibodies (anti-PAX6 [Biolegend], 1:70; anti-
insulin, 1:200) and a longer incubation with 
secondary antibody (2 h). Image acquisition was 
performed with a Zeiss Axio Observer inverted 
microscope fitted a Hamamatsu Flash4 
camera.  The filters used were: blue (365 nm LED; 
excitation 377/50; emission 477/60), green (470 nm 
LED; excitation 472/30; emission 520/35), red (540 
- 580 nm LED; excitation 534/20; emission 
572/28), and far red (625 nm LED; excitation 
631/22; emission 688/20). Negative controls to 
assess non-specific binding were performed by 
omitting the incubation with primary antibodies. 
Western (immuno-) blotting 
Whole islet extracts were separated using a 10% 
acrylamide gel and blotted onto a polyvinylidene 
difluoride membrane. Following blocking for 60 
min. with 5% (w/v) skimmed milk in TBST (10 
mM Tris-base, pH 7.6, 150 mM NaCl, 0.1% Tween 
20) membranes were incubated overnight at 4
o
C 
with antibody an against Pax6 (1:300, Biolegend). 
The membrane was washed three times (5 min. 
each) with TBST before incubation of the 
secondary anti-rabbit HRP antibody (1:5000) for 1 
hr. An enhanced chemiluminescence (ECL) system 
(Amersham Biosciences; GE Healthcare) was used 
for activation according to the manufacturer’s 
guidelines. The film was then exposed for 3 s and 
developed on a Xograph Compact X5 film 
processor. The membrane was then stripped for 
incubation with rabbit anti-tubulin (1:5000) as a 
loading control, and then re-exposed as above (5s).  
Ca
2+ 
imaging and connectivity analysis 
Isolated islets were incubated (37°C, 95% O2/5% 
CO2) for 1 h in fluo2-AM (10 μM; Teflabs, Austin, 
USA) diluted in a HEPES-bicarbonate buffer 
solution (120 mM NaCl, 4.8 mM KCl, 1.25 mM 
NaH2PO4, 24 mM NaHCO3, 2.5 mM CaCl2, 1.2 
mM MgCl2, 10 mM HEPES and 3 mM D-glucose; 
all Sigma). Functional multicellular Ca
2+
 imaging 
was achieved using a Nipkow spinning disk head, 
allowing rapid scanning of islet areas for long 
periods of time with minimal phototoxicity. A 
solid-state laser (CrystaLaser) controlled by a laser-
merge module (Spectral Applied Physics) provided 
wavelengths of 491 nm to excite fluo-2 (rate = 
0.5Hz; exposure time = 600 ms). Emitted light was 
filtered at 525/50 nm, and images captured with a 
highly sensitive 16-bit, 512 × 512 pixel back-
illuminated EM-CCD camera (ImageEM 9100-13; 
Hamamatsu). Volocity
TM
 software (PerkinElmer) 
provided the user interface. During recordings, 
islets were maintained at 35°C to 36°C and 
continuously irrigated with bicarbonate buffer 
aerated with 95% O2/5% CO2. Connectivity 
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analysis was performed as previously described 
(8,45). 
 
Measurement of insulin secretion in vitro. 
Insulin secretion was measured in batch 
incubations essentially as described (63). In brief, 
batches of 20 islets from βPax6 KO or control mice 
were subjected to glucose-stimulated insulin 
secretion assay one week after tamoxifen 
administration (n=3 animals/genotype). Islets were 
incubated for 30 min. sequentially in 3 mM then 17 
mM glucose. Islets were then lysed in lysis buffer 
(50 mM Tris.Cl pH 8.0, 150 mM NaCl, 1% v/v 
IGEPAL-C130) and nuclei pelleted. Insulin content 
of secreted and total fractions was determined by 
HTRF assay and normalised to DNA content of the 
nuclear fraction, assayed using CyQuant 
fluorescent dye. 
ATP/ADP imaging 
Islets were infected with an adenovirus containing 
cDNA encoding the ATP sensor Perceval (41) for 
48 h to measure intracellular ATP dynamics. 
Excitation of the fluorescent probe was achieved 
using a 491 nm laser (Spectral Applied Physics; 
rate = 0.2 Hz; exposure time 600 ms). Emitted light 
was filtered at 525/50 nm and images captured as 
for Ca
2+
 imaging.  
 
Total internal reflectance of fluorescence (TIRF) 
analysis 
 
Islets were infected with an adenovirus encoding 
NPY(neuropeptide Y)-venus as described (64). 
Islets were dissociated as described (65) and the 
liberated cells allowed to adhere to poly-L-lysine-
treated sterile glass slides for 24 h post transfection. 
Cells were then incubated for 1 h in HEPES-
bicarbonate buffer (see Ca
2+
 imaging analysis) 
containing 3mM glucose at 37 °C. Fixation was 
performed by incubating the slides for 1h at room 
temperature for at room temperature in PBS 
supplemented with 4% (v/v) paraformaldehyde.  
 
Imaging was performed as described  (66) using a 
Nikon Eclipse Ti microscope equipped with a 
100x/1.49NA TIRF objective, a TIRF/FRAP iLas2 
module o control laser angle (Roper Scientific), a 
Quad Band TIRF Filter Cube (TRF89902 – 
Chroma). NPY-venus, localised in insulin-secreting 
vesicles (67), was excited using a 488 nm laser 
line, and images were acquired with an ORCA-
Flash 4.0 camera (Hamamatsu) and Metamorph 
software (Molecular Device) was used for data 
capture. Laser angle was selected for an imaged 
section thickness of 150 - 180 nm. Images were 
analysed on ImageJ using a home-made macro. The 
script of the macro is available upon request.  
Statistical analysis 
Statistical significance was assessed using 
Student’s t-test. Two-way ANOVA (with 
Bonferroni or Sidak multiple comparison test) was 
used to examine the effect of multiple variables. 
Statistical analyses were performed using Graph 
Pad Prism 7.0, ImageJ and IgorPro. Values 
represented are the mean ± SD. 
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. Figure Legends 
Figure 1: Inducible deletion of Pax6 from pancreatic  cells does not affect β-cell mass 
(A) Gene deletion was caused by tamoxifen-induced Pdx1CreER-mediated removal of exons 5, 5a and 6 of 
Pax6. (B) qRT-PCR (**p<0.01; Student’s t-test; n=5 each genotype. Values represent mean ± SD) and (C) 
Western (immuno-) blot analysis of islets isolated from βPax6KO (Cre+) and litter mate controls (Cre-) mice. 
Note the presence of a lower molecular mass band in the Cre
+
 case reflecting the likely generation of a truncated 
Pax6 protein lacking exons 5 and 6. (D-F) Immunocytochemical analysis was performed as given under 
Experimental procedures. Pancreatic slices from wild-type controls (a-d) and PAX6 knockout mice (e-h) were 
stained for PAX6 (1:70), insulin (1:200) and glucagon (1:500) (scale bar = 50 µm). Images show staining of 
PAX6 (a, e), glucagon (b, f) and insulin (c, g). All channels were overlaid into a composite image with Dapi 
staining to visualise nuclear staining (d, h). (i) Percentage of PAX6-positive nuclei was significantly decreased 
in βPax6KO in whole islet cell populations compared to and litter mate controls. (****p<0.0001; Student’s t-
test; n=4 each genotype). (j) Percentage of PAX6 positive nuclei in beta was significantly decreased in 
βPax6KO mice. (****p<0.0001; Student’s t-test; n=5 each genotype). A significant but smaller reduction in 
PAX6 positive nuclei was present in α cells. Values represent mean ± SD. β-cell mass and α-cell mass represent 
the percentage of respectively insulin- (G) and glucagon- (H) positive staining area over the total pancreas 
section using ImageJ software. β to α cell ratio (I) was obtained by measuring the total insulin/glucagon-positive 
area on each pancreas section. A total of five pancreas sections, evenly separated by 25 μm, from each animal 
and genotype were used (n=4 animals in each group; p=ns by Student’s t test). Scale bar in D, 50 μm. 
 
Figure 2: Deletion of Pax6 in the  cell causes severe hyperglycaemia and reduces insulin levels. 
(A) Fed glycaemic profile and (B) accompanying body weight of βPax6KO and littermate control mice (n=2 
Cre
-
 and 4 Cre
+
 mice). (C) Challenging mice with a 0.75 U/Kg body weight insulin injection showed normal 
insulin sensitivity, despite severe hyperglycaemia (*p<0.05, ****p<0.0001, two-way ANOVA; n=6 animals 
each genotype). Upon termination 2 weeks post tamoxifen treatment (D), glucose levels were increased 
(****p<0.0001; Student’s t-test; n=7 Cre- and 6 Cre+ mice) coupled with (E) decreased insulin levels (*p<0.05; 
Student’s t-test; n=4 Cre- and 3 Cre+ mice). (F) Five islets were lysed in acidified ethanol and insulin content 
determined by HTRF assay (*p<0.05; Student’s t-test; n=14 Cre- and 12 Cre+ replicates). (G). Insulin secretion 
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from isolated islets (see Experimental for details). **p<0.05 by Student’s t-test for the effect of Pax6 deletion. 
(H) TIRF analysis of granule distribution involving n=30 separate cells for control, n=26 for null mouse islets.  
(I) Analysis of data obtained as in (H). Values represent mean ± SD. 
Figure 3: Islet gene expression is altered by Pax6 deletion. 
RNA was extracted from islets isolated from βPax6KO and littermate control mice, reverse transcribed before 
assessment of gene expression. Expression of Ins2 (A; **p<0.01), Slc30a8 (B; *p<0.05), Mafa (C; 
****p<0.0001), Slc2a2 (D, ***p<0.001), Glp1r (E; *p<0.05), Gck (F, ns), Slc16a1 (G, *p<0.05), Ldha (H, ns), 
Gjd2 (I, ns), Gcg (J, ns) and Ghrl (K, *p<0.05; all paired Student’s t-test vs. Cre-; n=3-4 each genotype) was 
assessed in both βPax6KO and littermate control mice. Values represent mean ± SD. (L) GSEA for disallowed 
genes (see Results).  (M, N) Genes with increased (green) or decreased (red) expression in βPax6KO versus 
control mice, based on RNAseq analysis.  
Figure 4: βPax6KO islets exhibit reduced insulin positive cells but retain neuroendocrine properties. 
(A) Pancreatic slices were stained for chromogranin A (1:200), insulin (1:200) and glucagon (1:1000) (scale bar 
= 50 μm). (B) Quantification of islet insulin:chromogranin A ratio (p<0.001; Student’s t-test; n=50 Cre- and 75 
Cre
+
 islets). (C) as for (B), but glucagon:chromogranin A ratio (ns; Student’s t-test; n=37 Cre- and 70 Cre+ 
islets). Values represent mean  SD. 
Figure 5: Islets isolated from βPax6KO mice display altered glucose-evoked ATP responses. 
ATP rises in response to 11 mM glucose (A, representative traces) were reduced in βPax6KO islets (B; p<0.05; 
Student’s t-test; n=9 Cre- and 13 Cre+ islets). The number of cells that responded to 11 mM glucose was also 
substantially reduced (C&D; p<0.001; Student’s t-test; n=9 Cre- and 13 Cre+ islets). Similar findings were made 
using 8 mM glucose (E,F; p<0.001; Student’s t-test; n=25 Cre- and 25 Cre+ islets). Values represent mean  SD. 
Figure 6: βPax6KO islets exhibit altered Ca2+ dynamics. 
Nipkow spinning disk microscopy and the Ca
2+
 dye fluo2 were used to assess [Ca
2+
]i
 
dynamics in response to 11 
mM glucose (A; p<0.001; Student’s t-test; n=15 Cre- and 17 Cre+ islets) or to 8 mM glucose (B; <0.001; 
Student’s t-test; n=13 Cre- and 13 Cre+ islets). No differences were apparent in the response to depolarisation 
with KCl (C; ns; Student’s t-test; n=9 Cre- and 13 Cre+ islets). Values represent mean  SD. 
Figure 7: Islet cell Ca
2+ responses remain highly coordinated in βPax6KO islets. 
(A) Individual cellular Ca
2+
 responses from control (upper) and βPax6KO (lower) islets. (B) Percentage of 
glucose-responsive islet cells (ns; Student’s t-test; n= 15 Cre- and 17 Cre+ islets). Connectivity analysis of 
glucose-stimulated Ca
2+ 
traces revealed increases in both the percentage of correlated islet cell pairs (C; p=0.06) 
and correlative strength (D&E; *p<0.05; both Student’s t-test; n=15 Cre- and 17 Cre+ islets). Values represent 
mean  SD. 
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